CTLA4 and hypophysitis: For example, the commonly reported endocrine irAE following anti–CTLA-4 therapy with ipilimumab is hypophysitis, a side effect that is rarely observed after PD-1-antibody therapy, which may be partially due to complement-mediated inflammation via direct binding of an antibody with CTLA-4 expressed on pituitary cells [46, 47].